Kaidre Bendjama News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kaidre bendjama. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kaidre Bendjama Today - Breaking & Trending Today

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , France General , Cristina Smolenschi , Immunomodulatory Therapiesposter , Lucie Larguier , Lucas Walther , Christelle Demeusoit , Xavier Noiriel , Luis Manso , Brandon Malone , Nathalie Silvestre , Maud Brandely , Benoit Grellier , Transgene Euronext , Christianh Ottensmeier , Annette Tavernaro , Camille Jamet , Thierry Huss , Hakim Makhloufi , Gisele Lacoste , Marta Kurzawa , Gerardo Colon Otero , Eric Quemeneur , Yoshiko Yamashita , Kaidre Bendjama , Fadi Azar ,

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses

Press release content from Business Wire. The AP news staff was not involved in its creation.
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
April 9, 2021 GMT
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas. These data provide a clinical proof of concept for Transgene’s double deleted VV cop TK - RR - patented virus backbone: after IV administration, TG6002 reached the tumor, multiplied within tumor cells, and induced the local expression of its payload (the ....

United States , Emiliano Calvo , Lucie Larguier , Damien Carpentier , Philippe Cassier , Alain Sadoun , Sylvie Berrebi , Christiane Jungels , Transgene Euronext , Kaidre Bendjama , Victor Moreno , Bernard Doger , Citigate Dewe Rogerson , American Association For Cancer Research , Corporate Communications , Euronext Paris , American Association , Cancer Research , Maria De Miguel , Philippe Erbs , Poster Number , Molecular Therapy Oncolytics , Artificial Intelligence , Risk Factors , Universal Registration Document , Citigate Dewe ,

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Adm

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Adm
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United States , Emiliano Calvo , Lucie Larguier , Damien Carpentier , Philippe Cassier , Alain Sadoun , Christiane Jungels , Transgene Euronext , Kaidre Bendjama , Victor Moreno , Bernard Doger , American Association For Cancer Research , Corporate Communications , Regulatory News , Euronext Paris , American Association , Cancer Research , Maria De Miguel , Philippe Erbs , Poster Number , Molecular Therapy Oncolytics , Artificial Intelligence , Risk Factors , Universal Registration Document , ஒன்றுபட்டது மாநிலங்களில் , எமிலியானோ கால்வோ ,

Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences

Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that
members of Transgene s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences:
ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4:
Éric Quéméneur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session Where next with Oncolytics
about
Date Time: March 3
rd at 4.20pm (CET)
Royal Society Meeting on Immuno-oncology: How to get the immune system to beat cancer which will take place March 24-25: ....

Lucie Larguier , Transgene Euronext , Kaidre Bendjama , Sylvie Berrebi , Citigate Dewe Rogerson , Royal Society , Royal Society Meeting On , Anticancer Therapies Congress , Corporate Communications , Regulatory News , Euronext Paris , Executive Vice President , Chief Scientific Officer , Oncolytics About Antibody , Society Meeting , Annual European Neoantigen Summit , Project Leader , Personalized Cancer Vaccines , Artificial Intelligence , Risk Factors , Universal Registration Document , அரச சமூகம் , அரச சமூகம் சந்தித்தல் ஆன் , பெருநிறுவன தகவல்தொடர்புகள் , ஒழுங்குமுறை செய்தி , நிர்வாகி துணை ப்ரெஸிடெஂட் ,